Hepion Pharmaceuticals, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 42.2 million compared to USD 32.72 million a year ago. Basic loss per share from continuing operations was USD 11.8 compared to USD 9.4 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.15 USD | +2.69% | -1.71% | -64.51% |
05-21 | Hepion Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
04-22 | Sector Update: Health Care Stocks Increase Late Afternoon | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-64.51% | 6.13M | |
+9.83% | 118B | |
+10.80% | 106B | |
-10.84% | 23.4B | |
-1.69% | 22.1B | |
-10.23% | 18.34B | |
-41.92% | 16.59B | |
-15.11% | 15.97B | |
+6.62% | 14.03B | |
+17.53% | 11.67B |
- Stock Market
- Equities
- HEPA Stock
- News Hepion Pharmaceuticals, Inc.
- Hepion Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022